Mabwell's 'Global First' Drug Aims to Reshape Blood Cancer Treatment

SHANGHAI – April 16, 2026 – In a significant development for oncology, Shanghai-based Mabwell has received regulatory acceptance from China's National Medical Products Administration (NMPA) to begin clinical trials for a highly innovative cancer therapy. The drug, codenamed 6MW5311, is a first-of-its-kind bispecific antibody designed to combat some of the most aggressive and difficult-to-treat hematologic malignancies, including Acute Myeloid Leukemia (AML), Chronic Myelomonocytic Leukemia (CMML), and Multiple Myeloma (MM).

The NMPA's acceptance of the Investigational New Drug (IND) application marks a global milestone, positioning 6MW5311 as the world's first LILRB4/CD3 T-cell engager to enter human trials. This move not only offers a new ray of hope for patients with limited options but also signals the growing prowess of China's biopharmaceutical industry on the world stage.

A New Weapon in the Immunotherapy Arsenal

At the heart of this development is a sophisticated piece of bioengineering known as a T-Cell Engager (TCE). These therapies are designed to act as a bridge, physically connecting a patient's own immune T-cells directly to cancer cells. By doing so, they unleash the potent killing power of the immune system specifically against the tumor.

6MW5311 simultaneously targets two proteins: CD3, a marker on the surface of T-cells, and LILRB4, an immune checkpoint protein found to be highly expressed on the surface of AML and other myeloid cancer cells. The LILRB4 protein acts as a 'don't eat me' signal, helping cancer cells evade the immune system. By targeting it, 6MW5311 aims to strip away this protective cloak.

What truly sets Mabwell's drug candidate apart is its innovative '2+1' asymmetric molecular structure, which incorporates a unique steric hindrance design. This clever feature acts as a safety switch. The antibody's arm that binds to T-cells is partially obstructed, making it far less active in the absence of a tumor cell. Only when the antibody's other arms lock onto the LILRB4 target on a cancer cell does the structure change, fully exposing the T-cell binding site and triggering a targeted immune attack. This mechanism is designed to dramatically reduce the risk of systemic, off-target T-cell activation, a major cause of severe side effects like Cytokine Release Syndrome (CRS) that have challenged other TCE therapies.

Preclinical studies have bolstered confidence in this approach. According to Mabwell, 6MW5311 demonstrated potent cytotoxic activity against various tumor cell lines and patient-derived samples. In animal models of AML, the drug led to significant tumor inhibition, and impressively, achieved complete tumor clearance in models with high LILRB4 expression. These promising efficacy results were paired with a favorable safety profile in non-human primate studies.

Addressing a Critical Unmet Need in Blood Cancers

The potential impact of 6MW5311 is best understood in the context of the diseases it targets. AML is a fast-growing cancer of the blood and bone marrow with high mortality rates. Globally, over 172,000 new cases were diagnosed in 2022, a figure projected to climb to over 221,000 by 2035. For decades, the standard of care has been dominated by intensive chemotherapy and stem cell transplants, options that are not suitable for all patients and have limited success in relapsed cases. Crucially, no TCE therapies have yet been approved for AML or the related rare disease CMML, leaving a significant therapeutic void.

CMML, a disorder with features of both myelodysplastic syndrome and myeloproliferative neoplasms, currently has few effective treatments and carries a persistent risk of transforming into AML.

Multiple Myeloma, a cancer of plasma cells, has seen treatment paradigms evolve significantly with new drug classes. However, it remains largely incurable. Most patients eventually relapse, developing resistance to existing therapies. The discovery that LILRB4 is also highly expressed on multiple myeloma cells, particularly in relapsed and refractory cases, opens a vital new avenue for attack where others have failed.

For patients and families grappling with these diagnoses, the prospect of a therapy that can overcome treatment resistance and offer a better safety profile represents a profound source of hope.

Mabwell's Global Ambition on Display

The advancement of 6MW5311 is also a story of corporate strategy and global ambition. Mabwell, a publicly-traded company on the Shanghai STAR market, is not a newcomer to drug development. With a pipeline of over a dozen candidates, including four commercialized products and several others in late-stage trials, the company has established a fully integrated chain from research to manufacturing.

This IND acceptance in China is just the first step in a broader global plan. Mabwell announced its intention to formally submit an IND application to the U.S. Food and Drug Administration (FDA) in the second quarter of 2026. This parallel regulatory strategy underscores a clear intent to compete in the lucrative and highly competitive Western pharmaceutical markets, a trend increasingly seen among China's top-tier biotech firms.

This move places Mabwell at the forefront of a rapidly growing bispecific antibody market, which is projected to expand from approximately $12 billion in 2024 to over $50 billion by 2030. Success with a first-in-class asset like 6MW5311 would not only be a commercial boon but would also solidify the company's reputation as a global innovator.

Navigating the Competitive and Regulatory Gauntlet

While the 'global first' clinical trial application gives Mabwell a significant head start, the path forward is long and fraught with challenges. The field of immunotherapy is intensely competitive, and while Mabwell is the first to the clinic with a LILRB4/CD3 bispecific, other companies, such as Nanjing Leads Biolabs and Immune-Onc Therapeutics, are actively developing similar molecules in preclinical stages. The race to develop safer and more effective cancer therapies is a marathon, not a sprint.

Furthermore, IND acceptance is only the beginning of a multi-year journey through rigorous clinical trials. The drug must first prove its safety in Phase I trials before its efficacy can be systematically evaluated in larger Phase II and III studies. Many promising drug candidates fail to cross these hurdles due to unforeseen toxicity or insufficient effectiveness in human subjects.

However, the combination of a validated target, an innovative safety-engineered design, and strong preclinical data provides a solid foundation for the clinical development of 6MW5311. As the first patient is dosed, the oncology community will be watching closely, hopeful that this pioneering therapy can translate its early promise into a tangible new standard of care for patients battling these devastating blood cancers.